CA-VOXELDANCE
25.5.2021 07:14:09 CEST | Business Wire | Press release
Voxeldance , a leading provider of digital manufacturing software for additive 3D printing, today announced the appointment of Robert Yusin as Chief Operating Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005861/en/
Yusin will lead operations and collaborate with the executive team to drive global growth. He brings more than 25 years of global experience in manufacturing applications, security, network, storage, and cloud in software and hardware. He was formerly one of three founders at Oqton. He also served as Director of Sales/business development at Autodesk where he pioneered the Asia market for the Autodesk Consumer Group (ACG) division. His previous experience includes executive roles at Accelops (Fortinet), Trustwave, Symantec, Loglogic (TIBCO), McAfee, and StorageTek. Yusin has built and managed companies and functions from zero to $300+ million in revenue.
“Robert brings a tremendous record of success and I am excited to add him to the company’s executive team,” said Zhang Chaoxin, CEO of Voxeldance. “His experience with startups with successful exits and domain expertise in manufacturing will help Voxeldance expand operations to support the next phase of growth.”
“Voxeldance offers software solutions that will integrate with the end-to-end digital factory for customers and partners,” said Robert Yusin. “The leadership team has built a great company as evidenced by the portfolio of large enterprise customers and partners; I look forward to contributing to the team.”
Additional Resources:
Official website: https://www.voxeldance.com
Video site: https://www.youtube.com/channel/UC1d6KPoLhTjwREMPRuG2MFg?view_as=subscriber
Twitter: https://twitter.com/VoxelDance
Facebook: https://www.facebook.com/VoxelDance-666723630455229/
WeChat Public Number: VoxelDance
LinkedIn: http://www.linkedin.com/company/Voxeldance
Customer case studies and evaluations: https://voxeldance.com/blog
Sales inquiry: info@voxeldance.com
About Voxeldance:
Voxeldance is the recognized leader for manufacturing software solutions for additive 3D printing, with a high adoption rate in use with hardware technology partners and service bureaus that integrate Voxeldance flagship additive software with their solutions. Voxeldance products are secure, cost effective and are easily adaptable to integrate with existing technology for the digital factory. The software products are built on technology advancements that will proactively accelerate workflow processes allowing the operator to effectively streamline hours of time for operational improvements in supporting many vertical use cases. Voxeldance is headquartered in Shanghai China and can be found online at http://www.voxeldance.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005861/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom